The FDA released a Drug Safety Communication warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury.
Patients should stop taking Veozah immediately and seek medical attention, including liver blood testing, if they experience signs and symptoms that suggest liver problems such as feeling more tired than usual; nausea; vomiting; unusual itching; light-colored stools; yellowing of the eyes or skin, called jaundice; dark urine; swelling in the stomach area, called the abdomen; or pain in the right upper abdomen.
If you are taking Veozah or want to learn about whether Veozah may be right for you, talk to your health care professional about the risks and benefits of receiving Veozah and discuss any questions or concerns you may have, including about possible alternative treatments.
Veozah is a nonhormonal prescription medicine approved in May 2023 to reduce the frequency and severity of moderate to severe hot flashes caused by menopause.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!